Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral...
Wednesday, December 12, 2012, 2:45 PM ETAlnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral and increased its price target from $19 to $25. Piper notes that with the Tekmira litigation behind them, ALNY can now focus more on clinical progress. Specifically, the firm expects the drug developer to have Phase II data on its ALN-TTR02 this summer to prepare for pivotal studies by year-end, adding that ALNY also plans to file applications with the FDA on sub-cutaneous hemophilia therapy formulations of ALN-TTR02 and ALN-AT3.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles